Company Description
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
The company’s lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease.
4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
| Country | United States |
| Founded | 2013 |
| IPO Date | Dec 11, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 196 |
| CEO | David Kirn |
Contact Details
Address: 5858 Horton Street, Suite 455 EmeryVille, California 94608 United States | |
| Phone | 510 505 2680 |
| Website | 4dmoleculartherapeutics.com |
Stock Details
| Ticker Symbol | FDMT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $23.00 |
| CIK Code | 0001650648 |
| CUSIP Number | 35104E100 |
| ISIN Number | US35104E1001 |
| Employer ID | 47-3506994 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. David H. Kirn M.D. | Co-Founder, President, Chief Executive Officer and Director |
| Dr. John F. Milligan Ph.D. | Executive Chairman |
| Dr. Fariborz Kamal Ph.D. | Chief Technical Advisor |
| Theresa Janke | Co-Founder and Chief of Staff |
| Kristian Humer M.B.A. | Chief Financial Officer and Principal Financial and Accounting Officer |
| Julian Pei | Head of Investor Relations and Corporate Finance |
| Dr. Katy Barglow Ph.D. | Chief Technical Officer |
| Dr. Scott P. Bizily J.D., Ph.D. | Chief Legal Officer and Corporate Secretary |
| Dr. An Song Ph.D. | Chief Translational Medicine Advisor |
| Dr. Noriyuki Kasahara M.D., Ph.D. | Chief Scientific Advisor and Member of Scientific Advisory Board |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | ARS | Filing |
| Apr 28, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 7, 2026 | SCHEDULE 13G/A | Filing |
| Mar 30, 2026 | 8-K | Current Report |
| Mar 26, 2026 | SCHEDULE 13G/A | Filing |
| Mar 18, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 18, 2026 | 10-K | Annual Report |
| Mar 18, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |